Success Stories: Advancing Precision Medicine for Tuberculosis: NIW Approved After RFE for a Nigerian Genetic Epidemiology Researcher
Client’s Testimonial:
"I had an amazing experience with my lawyers. Everything went smoothly. I never even had to talk on the phone since the messages were so clear.”
On June 24th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student Researcher in the field of Genetic Epidemiology (Approval Notice).
General Field: Genetic Epidemiology
Position at the Time of Case Filing: Graduate Student Researcher
Country of Origin: Nigeria
State of Residence at the Time of Filing: California
Approval Notice Date: June 24th, 2026
Processing Time: 11 months, 22 days (Premium Processing Requested)
Case Summary:
Tuberculosis remains difficult to control because susceptibility and treatment response can vary across populations, social conditions, and genetic backgrounds. This NIW approval highlights a Nigerian genetic epidemiology researcher whose proposed endeavor focuses on developing multi-omics strategies to identify host genetic risk factors associated with tuberculosis susceptibility and resistance. At the time of filing, the client was continuing research aligned with infectious disease genomics, single-cell analysis, and precision medicine approaches for tuberculosis management.
Research with National Importance
In the petition, we demonstrated that the proposed endeavor has substantial merit and national importance because improved tuberculosis prevention and treatment require better tools for understanding who is most vulnerable and why. The filing connected the client’s work to the need for more precise diagnostics, targeted interventions, and therapeutic development, particularly as tuberculosis cases have risen again in the United States after years of decline. By integrating genomic, transcriptomic, and epidemiological data, the client’s research supports more effective infectious disease management for diverse populations.
Academic Contributions and Recognition
The petition documented 2 peer-reviewed journal articles and 1 first-authored abstract, with 13 citations reflecting independent reliance on the client’s work. To show impact beyond raw totals, we highlighted that two publications ranked among the top 20 percent most cited in Molecular Biology and Genetics for their publication years. The filing also emphasized National Institutes of Health-supported research activity, which helped demonstrate that the client’s work aligns with nationally important public health priorities.
Expert Endorsements
The petition included expert letters explaining why the client’s tuberculosis research is important to infectious disease prevention, precision medicine, and more inclusive public health strategies.
One expert noted:
“...[client]'s work fills an important knowledge gap in TB epidemiology, emphasizing the importance of local context, social mobility, and ancestry in disease progression in endemic, underrepresented populations.”
This statement reinforced the petition’s showing that the client’s work addresses a meaningful gap in TB research and supports more targeted approaches to disease prevention, diagnosis, and treatment for diverse populations.
NIW Approval and Outlook
The I-140 NIW petition was filed on July 2nd, 2025. After USCIS issued a Request for Evidence (RFE) on January 7th, 2026, the case was approved on June 24th, 2026, following a Premium Processing upgrade after filing. In the filing and RFE response, we presented a focused NIW showing that the endeavor carries substantial merit and national importance, and that the client is well positioned through peer-reviewed publications, independent citation reliance, citation-percentile evidence, funded research activity, expert support, and a clear plan to continue advancing multi-omics approaches for tuberculosis precision medicine.